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of Medicine, Faculty of Medicine, Universidad Complutense, Madrid, SpainAbstractWe aimed to identify risk factors associated with the development
of haematogenous metastatic osteoarticular infection (MOI) after
an episode of Staphylococcus aureus bacteraemia (SAB). We
followed 198 patients with SAB during a median of 68.9 months.
Nine (4.54%) developed an MOI (median: 6.77 months) after
SAB. Factors associated with MOI were the presence of joint
prosthesis (hazard ratio 17.56; 95% CI 4.48–68.85) and
osteoporosis (hazard ratio 8.46; 95% CI 1.9–37.57). MOI is a
common complication after SAB and is related to high morbidity
and mortality. Patients with previous osteoarticular disease are at
the greatest risk of developing this complication.
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p://dx.doi.org/10.1016/j.cmi.2015.06.025IntroductionPatients with Staphylococcus aureus bacteraemia (SAB) are at
high risk of haematogenous seeding, and infectious compli-
cations including metastatic osteoarticular infection (MOI),
which generally occur within the ﬁrst 3 months after SAB
[1–3].
The real time frame for this increased risk, whether it is
limited to 3 months or goes beyond 6 months follow-up, re-
mains unknown [4–10]. Moreover, the speciﬁc risk factors for
the development of MOI are also unknown. Our aim was to
evaluate the risk of MOI after an episode of SAB including a long
follow-up period.Materials and methodsWe performed an observational-retrospective study of all adult
patients with SAB evaluated from January 2002 through
December 2004 in our centre.
Follow up of this cohort was performed from hospital
discharge until June 2014 by review of electronic records
(including re-admissions in our centre and visits with the
primary-care physician), or by telephone contact with the pa-
tient or his/her family.
The MOI was considered to be derived from the previous
SAB episode if it fulﬁlled the following criteria: (a) a new
valuable sample (i.e. blood, joint aspirate, or tissue biopsy)
yielded S. aureus with the same susceptibility proﬁle as the in-
dex SAB (the retrospective nature of our work precluded
obtaining molecular analyses); (b) the ﬁrst episode of SAB was
not associated with an osteoarticular infection; (c) in patients
with a joint prosthesis, the device had to have been placed 6
months before the index SAB; (d) at the time of MOI, there was
no contiguous osteoarticular infection [11]. Risk-time was
deﬁned as the period between the ﬁrst S. aureus-positive blood
culture and the development of the event or the end of follow
up. Other study deﬁnitions are depicted in the Supplementary
material.
Continuous variables were compared with the Student’s t
test or the Mann–Whitney U test, as appropriate, whereas
categorical parameters were compared using Fisher’s exact
test. Kaplan–Meier curves and Cox regression were used to
analyse risk factors associated with MOI. IBM SPSS Statistics
19.0 was used for statistical analysis.ious Diseases. Published by Elsevier Ltd. All rights reserved
CMI Lalueza et al. Osteoarticular infection after S. aureus bacteraemia 1010.e2ResultsThe ﬂow-chart of inclusion in the study is shown in the Sup-
plementary material (Fig. S1) and the features of the 198 pa-
tients included are shown in Table 1.
The mean follow up was 68.92 ± 52.24 months, (maximum
144.52 months). Nine patients (4.5%) developed MOI during
the follow up (see Supplementary material, Table S1) after a
mean time of 206.7 ± 189.8 days (maximum 588 days). MOI
was the ﬁrst cause of late metastatic complication, followed by
infective endocarditis in eight patients (4.04%). The most
common presentation was arthritis (found in six patients, ﬁve
with previous joint prostheses), spondylitis (two patients) andTABLE 1. Characteristics of the 198 patients followed after the Sta
Variable
Total
(n [ 198)
With MOI
(n [ 9)
Age (years) 61.76 ± 17.38 70.64 ± 19.25
Sex (male) 134 (67.7%) 4 (44.4%)
Haemodialysis 15 (7.6%) 1 (11.1%)
Endovascular prosthetic device 24 (12.1%) 1 (11.1%)
Diabetes mellitus 38 (19.2%) 2 (22.2%)
Immunosuppressive therapy 23 (11.6%) 2 (22.2%)
Tumoral disease 56 (28.3%) 1 (11.1%)
Use of steroids 18 (9.1%) 3 (33.3%)
Previous hospital contact 56 (28.3%) 2 (22.2%)
Osteoarthrosis 29 (14.6%) 6 (66.7%)
Osteoporosis 8 (4%) 3 (33.3%)
Joint prosthesis 13 (6.6%) 5 (55.7%)
Osteosynthesis material 9 (4.5%) 2 (22.2%)
Rheumatoid arthritis 2 (1%) 1 (11.1%)
Seronegative arthritis 1 (0.5%) 0
Gout 5 (2.5%) 0
Primary bone tumour 1 (0.5%) 0
Systemic lupus erythematosus 1 (0.5%) 0
Other connective tissue diseases 2 (1%) 1 (11.1%)
Previous bone fracture 15 (7.6%) 1 (11.1%)
Bone metabolism diseases 1 (0.5%) 0
MRSA 55 (27.8%) 3 (33.3%)
No. of positive blood culture bottles 3.78 ± 2.62 3.22 ± 1.09
Persistent bacteraemiaa 8 (6.5%) 0
Duration of fever (days) 3.94 ± 3.46 3.43 ± 2.29
Nosocomial onset 167 (84.3%) 8 (88.9%)
Source of bacteraemiab
Catheter related 113 (58.5%) 4 (44.4%)
Osteoarticular infectionc 32 (16.8%) 1 (11.1%)
Wound infection 16 (8.3%) 2 (22.2%)
Infective endocarditis 31 (16,2%) 0
Mediastinitis 8 (4.1%) 0
Unknown source of bacteraemia 18 (9.4%) 1 (11.1%)
Complicated bacteraemia 32 (16.2%) 0
Severe sepsis 11 (5.6%) 0
Duration of admission (days) 44.58 ± 35.71 36.33 ± 20.77
Medical intrahospital complications after SAB 33 (16.7%) 1 (11.1%)
Time to appropriate therapy (days) 1.168 ± 1.75 1.77 ± 1.78
Delayed appropriate treatment >24 h 126 (63.6%) 6 (66.7%)
Delayed appropriate treatment >48 h 50 (25.3%) 5 (55.6%)
Use of intravenous dicloxacillin sodiumd 115 (58.1%) 6 (66.7%)
Proportion of less than optimal duration of treatment 59 (30.6%) 5 (55.6%)
Duration of appropriate treatment (days) 20.06 ± 14.04 21.33 ± 15.77
Data are n (%), where n indicates the number of patients; or as expressed as mean ± SD.
HR, hazard ratio; MRSA, methicillin-resistant Staphylococcus aureus; SAB, Staphylococcus aureu
aResults are given according to the number of patients with a control blood-culture. Thus w
obtained in 123 patients (2 in the MOI group vs.121 in the group without MOI).
bThe percentage does not necessarily sum to 100 given that it was possible to codify more
cPrevious osteoarticular infection appeared in a different site than the MOI (see case numbe
dPatients treated with intravenous penicillinase-stable penicillin (dicloxacillin sodium). Note
eDue to the paucity of events in the study cohort we could not perform a multivariate Cox
exploratory analysis of major signiﬁcant variables obtained in the univariate analysis adjusting e
included a maximum of two variables. Final models after adjusting by pairs with the followin
osteosynthesis material and delayed appropriate treatment >48 h. The potential risk factors
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infeosteosynthesis-related osteomyelitis (one patient). The most
frequent sources of SAB were intravenous catheters (44%).
Three out of nine cases were due to methicillin-resistant
Staphylococcus aureus.
Kaplan–Meier survival curves for MOI cases according to
the presence of different potential risk factors are shown in
Fig. 1 and risk factors analysis for the development of MOI is
depicted in Table 1. Independent signiﬁcant risk factors asso-
ciated with MOI were the presence of joint prosthesis (hazard
ratio 17.56; 95% CI 4.48–68.85) and osteoporosis (hazard ratio
8.46; 95% CI 1.9–37.57). Indeed, ﬁve out of 13 patients (38%)
with joint prostheses developed MOI.
Two patients died, so the attributable mortality rate was
22.2% in the MOI group. Two other patients remained withphylococcus aureus bacteraemia
Without MOI
(n [ 189) p
Univariate
HR (95% CI)
Multivariatee
HR (95% CI) p
61.33 ± 17.23 0.031
130 (68.8%) 0.15
14 (7.4%) 0.51
23 (12.2%) 1
36 (19%) 0.68
21 (11.1%) 0.28
55 (29.1%) 0.45
15 (7.9%) 0.038 5.51 (1.37–2.07)
54 (28.6%) 1
23 (12.2%) <0.0001 11.21 (2.8–4.84)
5 (2.6%) 0.003 11.99 (2.99–48.04) 8.46 (1.9–37.57) 0.005
8 (4.2%) <0.0001 20.75 (5.55–77.57) 17.56 (4.48–68.85) <0.0001
7 (3.7%) 0.056 5.91 (1.22–28.47)
1 (0.5%) 0.089
1 (0.5%) 1
5 (2.6%) 1
1 (0.5%) 1
1 (0.5%) 1
1 (0.5%) 0.089
14 (7.4%) 0.51
1 (0.5%) 1
52 (27.5%) 0.71
3.80 ± 2.67 0.97
8 (6.6%) 0.87
4.01 ± 3.59 0.48
159 (84.1%) 1
109 (59.2%) 0.49
31 (17%) 1
14 (7.7%) 0.166
31 (17%) 0.359
8 (4.3%) 1
17 (9.3%) 0.59
32 (16.9%) 0.36
11 (5.8%) 1
44.97 ± 36.26 0.479
32 (16.9%) 1
1.132 ± 1.75 0.28
120 (63.5%) 1
45 (23.8%) 0.047 3.94 (1.06–14.71)
109 (57.7%) 0.49
54 (29.3%) 0.135
20.005 ± 14 0.98
s bacteraemia.
as obtained following the treating physician’s criterion. Control blood-cultures were
than one initial diagnosis related to the SAB episode.
r 7 in the Supplementary material, Table S1).
that all patients with MRSA bacteremia received vancomycin.
regression model including all the major potential risk factors. Instead we did an
ach variable with all other variables by performing different Cox regression models that
g variables were: use of steroids, osteoarthrosis, osteoporosis, joint prosthesis,
that were constantly retained in the different models are marked in bold.
ctious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1010.e1–1010.e5
FIG. 1. Kaplan–Meier estimate of the survival function in metastasic osteoarticular infection (MOI) cases according to the presence of osteoarthrosis
(a), previous use of steroids (b), presence of osteoporosis (c), presence of previous joint prosthesis (d), presence of osteosynthesis material (e) and
delayed appropriate treatment of Staphylococcus aureus bacteraemia more than 48 h (f). Considering that the maximum period of time until the event
(long-term MOI) has been 588 days, the scale of the Kaplan–Meier curve was truncated to 2 years of follow up.
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CMI Lalueza et al. Osteoarticular infection after S. aureus bacteraemia 1010.e4severe incapacitating sequelae. Only one patient recovered
completely.DiscussionThis study differs from previous studies [4,7,9,10] in that we
completed an extended follow-up period of patients with SAB
(mean follow up was 68.9 months). Although we observed no
MOI beyond 24 months after the episode of SAB, there were
three cases (33%) that would not have been detected if follow
up had been <6 months.
We observed strict clinical criteria that allowed us to select
only those cases in which the late osteoarticular infection
occurred as a distance seeding from a septic focus after initial
SAB, hence excluding recurrences in the same location of a
previous osteoarticular infection that could have happened
during the SAB. Considering these criteria we found nine cases
of MOI (4.54%), therefore constituting the most common late
complication of SAB, observing high morbidity and mortality.
Previous musculoskeletal disease and especially, the presence of
prosthetic material and osteoporosis before the development
of SAB were the main factors encouraging S. aureus osteo-
articular seeding after an episode of bacteraemia [12–14].
Indeed, the presence of joint prosthetic material posed a 17-
fold increased risk for MOI development. The risk of bacterial
seeding on a prosthetic joint has been reported to be between
29% and 34% in other series [12–14]. We must also take into
account that a high percentage of them might go unnoticed
[13–15]. We only reported three patients presenting MOI not
related to osteoarticular prosthetic material. Of note, all of
them had some type of bone disease (osteoarthritis, osteopo-
rosis or rheumatoid arthritis), two patients were receiving
steroids and in two patients appropriate treatment was delayed
for more than 48 h, this being related with a four-fold increased
risk of MOI in the univariate analysis. In previous studies, the
delay in the initiation of SAB treatment has been considered a
risk factor of poor outcome within 30 days of the SAB [16,17].
However, there are no previous data on its impact in long-term
complications.
Potential limitations of this study are (a) its single-centre
design, which hampers the generalization of our ﬁndings in
other settings; (b) its retrospective nature, with inherent biases;
and (c) the absence of molecular studies that would conﬁrm the
clonality of the Staphylococcus strain causing MOI and the index
bacteraemia isolate. Regarding this last item, however, we did
conﬁrm identical antibiotic resistance patterns and minimum
inhibitory concentration in the antimicrobial susceptibility
testing. In this regard, we cannot rule out the possibility of aClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infenew unrelated infection by a phenotypically identical S. aureus.
However, staphylococcal relapses after a long period of time
have been well described [18]. Finally, the absence of molecular
studies has also precluded us from including genetic parameters
and other virulence factors as potential predictors of MOI. The
expression of these virulence factors may be very different
between staphylococcal strains, regardless of the antimicrobial
susceptibility, as potential predictors of MOI [19].
In conclusion, MOI is a common long-term complication
after SAB and is related with a high morbidity and mortality, and
may pass overlooked in clinical practice, especially with short
follow-up periods. We therefore recommend monitoring these
patients for at least 2 years, especially in the presence of pre-
vious musculoskeletal pathology and/or orthopaedic material.FundingThis study was supported by internal funding. J.L-T was sup-
ported by a grant from the Instituto de Salud Carlos III [CD14/
00176].Transparency declarationsThe authors declare no conﬂicts of interest.AcknowledgementsWe are grateful to Nerea Sáenz Madrazo for reviewing the
manuscript and to David Lora de Pablos and Paloma Ferrando
for the statistical assessment.Appendix A. Supplementary dataSupplementary data related to this article can be found at http://
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